According to the IRS, 51 CRCs showed low expression of TROP2 (IRS 2–3, 4.8%), 114 neoplasms showed moderate expression of TROP2 (IRS 4–8, 10.8%), and 49 carcinomas showed strong expression of TROP2 (IRS 9–12, 4.7%). This evidence concerns the gene TACSTD2 and neoplasm.